![Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes | Leukemia Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fleu.2017.122/MediaObjects/41375_2017_Article_BFleu2017122_Fig3_HTML.jpg)
Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes | Leukemia
![Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study - The Lancet Oncology Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2045959899/2057173040/gr1.gif)
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study - The Lancet Oncology
![Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma - ScienceDirect Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120425893-grabsf1.jpg)
Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma - ScienceDirect
![Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma | Future Oncology Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon.15.123/asset/images/medium/figure1.gif)
Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma | Future Oncology
![Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials - ScienceDirect Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S247395292030954X-grabsf1.jpg)
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials - ScienceDirect
![Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Leukemia Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Leukemia](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-019-0517-6/MediaObjects/41375_2019_517_Fig1_HTML.png)
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Leukemia
![Final ASPIRE Results Confirm Survival Benefit With Carfilzomib Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma Final ASPIRE Results Confirm Survival Benefit With Carfilzomib Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma](https://apps.hematology.org/images/acn/2018/03/ACN_4.4_SUPP_Table-3.jpg)
Final ASPIRE Results Confirm Survival Benefit With Carfilzomib Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma
![Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR | Leukemia Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR | Leukemia](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41375-020-01049-5/MediaObjects/41375_2020_1049_Fig1_HTML.png)
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR | Leukemia
![Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data | SpringerLink Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11136-019-02307-5/MediaObjects/11136_2019_2307_Fig1_HTML.png)
Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma, based on German benefit assessment data | SpringerLink
![Progression-free survival in the ENDEAVOR trial. A, early relapsers; B,... | Download Scientific Diagram Progression-free survival in the ENDEAVOR trial. A, early relapsers; B,... | Download Scientific Diagram](https://www.researchgate.net/publication/323192017/figure/fig2/AS:594325847171073@1518709732526/Progression-free-survival-in-the-ENDEAVOR-trial-A-early-relapsers-B-late-relapsers.png)
Progression-free survival in the ENDEAVOR trial. A, early relapsers; B,... | Download Scientific Diagram
![PDF) Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III PDF) Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III](https://i1.rgstatic.net/publication/324224841_Response_and_progression-free_survival_according_to_planned_treatment_duration_in_patients_with_relapsed_multiple_myeloma_treated_with_carfilzomib_lenalidomide_and_dexamethasone_KRd_versus_lenalidomid/links/5accc3e4aca272abdc65c563/largepreview.png)